Genocea rises on six-month HSV-2 data

Genocea Biosciences Inc. (NASDAQ:GNCA) gained $0.49 to $6.39 after it said GEN-003 significantly reduced viral shedding in an interim analysis of a Phase II trial to treat herpes simplex virus-2 (HSV-2), meeting the study's primary endpoint.

Genocea reported a 58% reduction in viral shedding from baseline to six months after treatment with 60 ug per protein of GEN-003 and 75 ug of its Matrix-M2 adjuvant, the study's best performing dose (p<0.0001). Five of six GEN-003 doses significantly reduced genital lesions from baseline at rates ranging from 43-69%. ...